Author | Year | No of patients | Intervention | Outcome for CS patients |
---|---|---|---|---|
Merimsky et al.[23] | 2000 | 18 advanced sarcoma (3 CS) | Gemcitabine | 2 SD |
Skubitz et al.[24] | 2003 | 47 advanced sarcoma (1 CS) | Pegylated-liposomal doxorubicin | Not mentioned |
Nooij et al.[25] | 2005 | 37 bone sarcoma (16 CS) | Doxorubicin + cisplatin | 2 CR |
Group A: operable, non-metastatic (4 CS) | 3 SD | |||
Group B: inoperable, metastatic (12 CS) | ||||
Maki et al.[26] | 2009 | 145 advanced sarcoma (2 CS) | Sorafenib (multi-tyrosine kinase inhibitor) | Not mentioned |
Pacey et al.[27] | 2009 | 26 advanced sarcoma (2 CS) | Sorafenib(multi-tyrosine kinase inhibitor) | 1 SD |
Grignani et al.[28] | 2011 | 26 advanced chondrosarcoma | Imatinib mesylate (c-kit/PDGFR inhibitor) | 8 SD |
OS 11Â months | ||||
Fox et al.[29] | 2012 | 53 advanced sarcoma (25 CS) | Gemcitabine + docetaxel | 2 PR |
Italiano et al.[30] | 2012 | 40 advanced CS | GDC-0449/vismodegib (hedgehog inhibitor) | 4 SD (of first 17 patients) |
Schuetze et al.[31] | 2012 | 49 advanced sarcoma (2 CS) | Sirolimus (mTOR inhibitor) + cyclophosphamide | 1 SD |
Ha et al.[32] | 2013 | 36 advanced sarcoma | Cetuximab (EGFR antibody) | PD |
Group A: EGFR+ | ||||
Group B: EGFR- (1 CS) | ||||
Schwartz et al.[33] | 2013 | 388 advanced sarcoma | Cixutumumab (IGF1R antibody) + temsirolimus (mTOR-inhibitor) | Not mentioned |
Group A: IGF-1R + soft tissue sarcoma | ||||
Group B: IGF-1R + bone sarcoma (20 CS) | ||||
 |  | Group C: IGF-1R- sarcoma (18 CS) |  |  |